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Elevated total plasma homocysteine (tHcy) levels are
considered to be an independent risk factor for arteriosclerosis
and stroke. Prospective studies, however, have shown no or only
weak associations1. This has raised the question whether the
temporal sequence of sample collection and disease occurrence
may have impacted the study results of case control studies, i.e.
the timing of tHcy measurements relative to stroke onset is a
factor to be considered in the interpretation of results. To collect
data on the importance of the time point of plasma tHcy
measurement after stroke, we compared tHcy levels of acute
stroke with tHcy levels in the convalescent phase.
METHODS
We recruited patients with clinically and radiologically
proven acute stroke admitted to the Department of Neurology,
University of Bonn, Germany. Patients with transitory ischemic
attacks or lacunar ischemic stroke were excluded from the study.
Patients with concomitant diseases or medications that alter
tHcy, such as renal insufficiency or multivitamin therapy, were
excluded. Fasting venous blood samples were collected for
determination of plasma tHcy levels within three days after
stroke and during a follow-up examination after at least six
months. Total plasma homocysteine was determined by fully
automated particle-enhanced immunonephelometry with a BN II
System (Dade Behring). The reference value for this method is
5-10 µmol/l fasting tHcy.
Differences between the time points of homocysteine plasma
level measurement were calculated with the two-sided t-test for
paired samples. A p-value of ≤0.05 was considered statistically
significant. All patients gave written informed consent. The
study was approved by the local ethical committees.
RESULTS
Twenty-two patients were included in the study (47% women,
average age 47.9 ± 15.2 years). Fifteen patients were diagnosed
with thromboembolic ischemic stroke, four with sinus venous
thrombosis and stroke, and three with intracerebral hemorrhage.
The tHcy levels measured within one to three days after stroke
(12.3 ± 3.8µmol/l) were not significantly different from tHcy
levels measured during follow-up (13.6 ± 3.5µmol/l; p=0.22;
Figure) for all 22 patients and when patients with sinus
thrombosis and hemorrhagic stroke were excluded (not shown).
DISCUSSION
This study does not support the hypothesis that tHcy levels
are different in the first three days after stroke in comparison
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with the convalescent phase. The small sample size and the
heterogeneity of our sample allow for random errors and
replication of these data in a different and larger population is
warranted. Other studies have reported significantly lower
homocysteine levels immediately after a vascular event, but
rising levels during the next seven days2-4. Given the design of
our study, we cannot provide information on tHcy levels of days
three to seven. In summary, the present data suggest that
measurement of tHcy levels can be performed within the first
three days after stroke or in the convalescent phase without
relevant influence of the time point of measurement.
Figure: Box plot of tHcy plasma levels within the first three days after
stroke (1) and during follow-up (2). The top and bottom of the box show
the 25% and 75% percentile, the whiskers the 5% and 95% percentile.
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